{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:21:30Z","timestamp":1792754490042,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,9,18]],"date-time":"2007-09-18T00:00:00Z","timestamp":1190073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s10549-007-9548-1","type":"journal-article","created":{"date-parts":[[2007,9,17]],"date-time":"2007-09-17T12:11:14Z","timestamp":1190031074000},"page":"167-180","source":"Crossref","is-referenced-by-count":246,"title":["Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy"],"prefix":"10.1007","volume":"107","author":[{"given":"David","family":"Cella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,18]]},"reference":[{"key":"9548_CR1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"ATAC Trialists\u2019 Group","year":"2002","unstructured":"ATAC Trialists\u2019 Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) randomised trial. Lancet 359:2131\u20132139","journal-title":"Lancet"},{"key":"9548_CR2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5\u00a0years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362","journal-title":"Lancet"},{"key":"9548_CR3","doi-asserted-by":"crossref","unstructured":"Th\u00fcrlimann B, Keshaviah A, Coates AS et al, for the Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757","DOI":"10.1056\/NEJMoa052258"},{"key":"9548_CR4","doi-asserted-by":"crossref","unstructured":"Coombes RC, Hall E, Gibson LJ et al, for the Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092","DOI":"10.1056\/NEJMoa040331"},{"key":"9548_CR5","doi-asserted-by":"crossref","unstructured":"Jakesz R, Jonat W, Gnant M et al, on behalf of the ABCSG and the GABG (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2\u00a0years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455\u2013462","DOI":"10.1016\/S0140-6736(05)67059-6"},{"key":"9548_CR6","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2005.04.120","volume":"23","author":"F Boccardo","year":"2005","unstructured":"Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23:5138\u20135147","journal-title":"J Clin Oncol"},{"key":"9548_CR7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262\u20131271","journal-title":"J Natl Cancer Inst"},{"key":"9548_CR8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/jco.2005.23.16_suppl.527","volume":"23","author":"R Jakesz","year":"2005","unstructured":"Jakesz R, Samonigg H, Greil R et al (2005) Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23:526 (abstract)","journal-title":"J Clin Oncol"},{"key":"9548_CR9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619\u2013629","journal-title":"J Clin Oncol"},{"key":"9548_CR10","unstructured":"National Comprehensive Cancer Network (2005) Breast cancer: clinical practice guidelines in oncology \u2013 v.2.2005. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf . Cited 14 June 2005"},{"key":"9548_CR11","doi-asserted-by":"crossref","first-page":"1056s","DOI":"10.1158\/1078-0432.CCR-05-2185","volume":"12","author":"TJ Whelan","year":"2006","unstructured":"Whelan TJ, Pritchard KI (2006) Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 12:1056s\u20131060s","journal-title":"Clin Cancer Res"},{"key":"9548_CR12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/annonc\/mdj141","volume":"17","author":"AH Partridge","year":"2006","unstructured":"Partridge AH (2006) Non-adherence to endocrine therapy for breast cancer. Ann Oncol 17:183\u2013184","journal-title":"Ann Oncol"},{"key":"9548_CR13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","volume":"21","author":"AH Partridge","year":"2003","unstructured":"Partridge AH, Wang PS, Winer EP et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602\u2013606","journal-title":"J Clin Oncol"},{"key":"9548_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/annonc\/mdj044","volume":"17","author":"L Fallowfield","year":"2006","unstructured":"Fallowfield L, Atkins L, Catt S et al (2006) Patients\u2019 preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205\u2013210","journal-title":"Ann Oncol"},{"key":"9548_CR15","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ejca.2006.03.004","volume":"42","author":"L Atkins","year":"2006","unstructured":"Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271\u20132276","journal-title":"Eur J Cancer"},{"key":"9548_CR16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","volume":"99","author":"TL Lash","year":"2006","unstructured":"Lash TL, Fox MP, Westrup JL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215\u2013220","journal-title":"Breast Cancer Res Treat"},{"key":"9548_CR17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pec.2004.10.005","volume":"59","author":"EA Grunfeld","year":"2005","unstructured":"Grunfeld EA, Hunter MS, Sikka P et al (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97\u2013102","journal-title":"Patient Educ Couns"},{"key":"9548_CR18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdi158","volume":"16","author":"KM Wasan","year":"2005","unstructured":"Wasan KM, Goss PE, Pritchard PH et al (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5\u00a0years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707\u2013715","journal-title":"Ann Oncol"},{"key":"9548_CR19","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00520-006-0085-y","volume":"14","author":"JA Sloan","year":"2006","unstructured":"Sloan JA, Frost MH, Berzon R et al (2006) The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer 14:988\u2013998","journal-title":"Support Care Cancer"},{"key":"9548_CR20","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","volume":"22","author":"L Fallowfield","year":"2004","unstructured":"Fallowfield L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261\u20134271","journal-title":"J Clin Oncol"},{"key":"9548_CR21","doi-asserted-by":"crossref","unstructured":"Cella D, Fallowfield L, on behalf of the ATAC Trialists\u2019 Group (2005) Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the arimidex (A), tamoxifen (T), alone or in combination (ATAC) trial. J Clin Oncol 23:577 (abstract)","DOI":"10.1200\/jco.2005.23.16_suppl.577"},{"key":"9548_CR22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","volume":"100","author":"D Cella","year":"2006","unstructured":"Cella D, Fallowfield L, Barker P et al (2006) Quality of life of postmenopausal women in the ATAC (\u201cArimidex\u201d, tamoxifen, alone or in combination) trial after completion of 5\u00a0years\u2019 adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273\u2013284","journal-title":"Breast Cancer Res Treat"},{"key":"9548_CR23","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.1200\/jco.2006.24.18_suppl.10597","volume":"24","author":"C Massacesi","year":"2006","unstructured":"Massacesi C, Zepponi L, Rocchi MB et al (2006) Tamoxifen-related endocrine symptoms in early breast cancer patients are relieved when it is switched to anastrozole. J Clin Oncol 24:10597 (abstract)","journal-title":"J Clin Oncol"},{"key":"9548_CR24","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2005.03.3654","volume":"24","author":"LJ Fallowfield","year":"2006","unstructured":"Fallowfield LJ, Bliss JM, Porter LS et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910\u2013917","journal-title":"J Clin Oncol"},{"key":"9548_CR25","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1200\/JCO.2005.11.181","volume":"23","author":"TJ Whelan","year":"2005","unstructured":"Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5\u00a0years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931\u20136940","journal-title":"J Clin Oncol"},{"key":"9548_CR26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1010684903199","volume":"66","author":"D Fellowes","year":"2001","unstructured":"Fellowes D, Fallowfield LJ, Saunders CM et al (2001) Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for \u2018well-tolerated\u2019 treatments?. Breast Cancer Res Treat 66:73\u201381","journal-title":"Breast Cancer Res Treat"},{"key":"9548_CR27","unstructured":"Coombes C, Bliss J, Hall E et al (2003) Under-reporting of symptoms in patients with early breast cancer (EBC) who have received tamoxifen treatment for 2\u20133\u00a0years. Proc Am Soc Clin Oncol 22:13 (abstract 48)"},{"key":"9548_CR28","unstructured":"Fallowfield L, Cella D, on behalf of the ATAC Trialists\u2019 Group (2002) Assessing the quality of life (QOL) of postmenopausal women randomized into the ATAC (\u2018arimidex\u2019, tamoxifen, alone or in combination) adjuvant breast cancer trial. Poster presented at: American Society of Clinical Oncology 38th Annual Meeting; May 18\u201321, 2002; Orlando, FL"},{"key":"9548_CR29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","volume":"7","author":"A Buzdar","year":"2006","unstructured":"Buzdar A, Howell A, Cuzick J et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633\u2013643","journal-title":"Lancet Oncol"},{"key":"9548_CR30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/01.cco.0000180434.31991.bf","volume":"17","author":"L Morales","year":"2005","unstructured":"Morales L, Neven P, Paridaens R (2005) Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 17:559\u2013565","journal-title":"Curr Opin Oncol"},{"key":"9548_CR31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78\u201384","journal-title":"J Clin Oncol"},{"key":"9548_CR32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1188\/05.ONF.343-353","volume":"32","author":"PH Viale","year":"2005","unstructured":"Viale PH (2005) Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment. Oncol Nurs Forum 32:343\u2013353","journal-title":"Oncol Nurs Forum"},{"key":"9548_CR33","unstructured":"Taylor M, Rastelli A, Civitelli R et al (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Abstract presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8\u201311, 2004; San Antonio, TX"},{"key":"9548_CR34","first-page":"S205","volume":"17","author":"JN Thompson","year":"2006","unstructured":"Thompson JN, Napoli N, Civitelli R et al (2006) Effects of dietary calcium vs. calcium supplements on estrogen metabolism and bone density. Osteoporos Int 17:S205 (abstract P696MO)","journal-title":"Osteoporos Int"},{"key":"9548_CR35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W Jr et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36\u201343","journal-title":"Cancer"},{"key":"9548_CR36","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2006.03.022","volume":"33","author":"A Brufsky","year":"2006","unstructured":"Brufsky A (2006) Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 33:S13\u2013S17","journal-title":"Semin Oncol"},{"key":"9548_CR37","unstructured":"Anastrozole bisphosphonate study in postmenopausal women with hormone-receptor-positive early breast cancer. Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00082277 . Cited 10\u00a0October 2006"},{"key":"9548_CR38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11914-006-0012-7","volume":"4","author":"MR McClung","year":"2006","unstructured":"McClung MR (2006) Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. Curr Osteoporos Rep 4:28\u201333","journal-title":"Curr Osteoporos Rep"},{"key":"9548_CR39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11914-996-0014-5","volume":"3","author":"NAT Hamdy","year":"2005","unstructured":"Hamdy NAT (2005) Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 3:121\u2013125","journal-title":"Curr Osteoporos Rep"},{"key":"9548_CR40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.emc.2006.01.004","volume":"24","author":"L Harrington","year":"2006","unstructured":"Harrington L, Schneider JI (2006) Atraumatic joint and limb pain in the elderly. Emerg Med Clin N Am 24:389\u2013412","journal-title":"Emerg Med Clin N Am"},{"key":"9548_CR41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/08916930500285857","volume":"38","author":"P Sarzi-Puttini","year":"2005","unstructured":"Sarzi-Puttini P, Atzeni F, Capsoni F et al (2005) Drug-induced lupus erythematosus. Autoimmunity 38:507\u2013518","journal-title":"Autoimmunity"},{"key":"9548_CR42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000089991","volume":"69","author":"MM Abu-Khalaf","year":"2005","unstructured":"Abu-Khalaf MM, Windsor S, Ebisu K et al (2005) Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology 69:372\u2013383","journal-title":"Oncology"},{"key":"9548_CR43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1200\/JCO.2003.06.132","volume":"21","author":"SC Formenti","year":"2003","unstructured":"Formenti SC, Volm M, Skinner KA et al (2003) Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I\/II trial. J Clin Oncol 21:864\u2013870","journal-title":"J Clin Oncol"},{"key":"9548_CR44","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2001.19.10.2767","volume":"19","author":"PP Donnellan","year":"2001","unstructured":"Donnellan PP, Douglas SL, Cameron DA et al (2001) Aromatase inhibitors and arthralgia. J Clin Oncol 19:2767","journal-title":"J Clin Oncol"},{"key":"9548_CR45","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ejca.2005.10.028","volume":"42","author":"E McCloskey","year":"2006","unstructured":"McCloskey E (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044\u20131051","journal-title":"Eur J Cancer"},{"key":"9548_CR46","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/art.21364","volume":"52","author":"DT Felson","year":"2005","unstructured":"Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52:2594\u20132598","journal-title":"Arthritis Rheum"},{"key":"9548_CR47","unstructured":"Plourde P, Locker G, Hoctin-Boes G et al (2005) Arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk-benefit analysis. Poster presented at: 7th Annual Lynn Sage Breast Cancer Symposium; October 6\u20139 2005; Chicago, Illinois"},{"key":"9548_CR48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.critrevonc.2005.04.009","volume":"57","author":"CH Mom","year":"2006","unstructured":"Mom CH, Buijs C, Willemse PHB et al (2006) Hot flushes in breast cancer patients. Crit Rev Oncol Hematol 57:63\u201377","journal-title":"Crit Rev Oncol Hematol"},{"key":"9548_CR49","doi-asserted-by":"crossref","unstructured":"Holmberg L, Anderson H, for the HABITS Steering, Data Monitoring Committees (2004) HABITS (hormonal replacement therapy after breast cancer\u2014is it safe?), a randomised comparison: trial stopped. Lancet 363:453\u2013455","DOI":"10.1016\/S0140-6736(04)15493-7"},{"key":"9548_CR50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/annonc\/mdf151","volume":"13","author":"G Bertelli","year":"2002","unstructured":"Bertelli G, Venturini M, Del Mastro L et al (2002) Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 13:883\u2013888","journal-title":"Ann Oncol"},{"key":"9548_CR51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3816\/SCT.2006.n.004","volume":"3","author":"DL Barton","year":"2006","unstructured":"Barton DL, Loprinzi C, Atherton PJ et al (2006) Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Support Canc Ther 3:91\u201397","journal-title":"Support Canc Ther"},{"key":"9548_CR52","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO.2002.20.6.1578","volume":"20","author":"CL Loprinzi","year":"2002","unstructured":"Loprinzi CL, Sloan JA, Perez EA et al (2002) Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20:1578\u20131583","journal-title":"J Clin Oncol"},{"key":"9548_CR53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1008382706068","volume":"11","author":"V Stearns","year":"2000","unstructured":"Stearns V, Isaacs C, Rowland J et al (2000) A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 11:17\u201322","journal-title":"Ann Oncol"},{"key":"9548_CR54","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","volume":"289","author":"V Stearns","year":"2003","unstructured":"Stearns V, Beebe KL, Iyengar M et al (2003) Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289:2827\u20132834","journal-title":"JAMA"},{"key":"9548_CR55","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","volume":"356","author":"CL Loprinzi","year":"2000","unstructured":"Loprinzi CL, Kugler JW, Sloan JA et al (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356:2059\u20132063","journal-title":"Lancet"},{"key":"9548_CR56","first-page":"47","volume":"1","author":"DL Barton","year":"2003","unstructured":"Barton DL, Loprinzi CL, Novotny P et al (2003) Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 1:47\u201351","journal-title":"J Support Oncol"},{"key":"9548_CR57","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.2005.04.7324","volume":"24","author":"CL Loprinzi","year":"2006","unstructured":"Loprinzi CL, Levitt R, Barton D et al (2006) Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 24:1409\u20131414","journal-title":"J Clin Oncol"},{"key":"9548_CR58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30\u201339","journal-title":"J Natl Cancer Inst"},{"key":"9548_CR59","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","volume":"95","author":"V Stearns","year":"2003","unstructured":"Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758\u20131764","journal-title":"J Natl Cancer Inst"},{"key":"9548_CR60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","volume":"366","author":"KJ Pandya","year":"2005","unstructured":"Pandya KJ, Morrow GR, Roscoe JA et al (2005) Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 366:818\u2013824","journal-title":"Lancet"},{"key":"9548_CR61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/aim.23.4.171","volume":"23","author":"J Filshie","year":"2005","unstructured":"Filshie J, Bolton T, Browne D et al (2005) Acupuncture and self acupuncture for long term treatment of vasomotor symptoms in cancer patients\u2014audit and treatment algorithm. Acupunct Med 23:171\u2013180","journal-title":"Acupunct Med"},{"key":"9548_CR62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793\u20131802","journal-title":"N Engl J Med"},{"key":"9548_CR63","doi-asserted-by":"crossref","unstructured":"Schover LR (2005) Sexuality and fertility after cancer. Hematology (Am Soc Hematol Educ Program) 1:523\u2013527","DOI":"10.1182\/asheducation-2005.1.523"},{"key":"9548_CR64","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","volume":"17","author":"A Kendall","year":"2006","unstructured":"Kendall A, Dowsett M, Folkerd E et al (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584\u2013587","journal-title":"Ann Oncol"},{"key":"9548_CR65","first-page":"S332","volume":"15","author":"K Mok","year":"2006","unstructured":"Mok K, Mireskandari S, Juraskova I et al (2006) OVER (Olive oil Vaginal Exercises and Replens) Come. Psycho-Oncology 15:S332 (abstract 778)","journal-title":"Psycho-Oncology"},{"key":"9548_CR66","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM200009073431002","volume":"343","author":"JL Shifren","year":"2000","unstructured":"Shifren JL, Braunstein GD, Simon JA et al (2000) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682\u2013688","journal-title":"N Engl J Med"},{"key":"9548_CR67","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/01.GME.0000060256.03945.20","volume":"10","author":"R Goldstat","year":"2003","unstructured":"Goldstat R, Briganti E, Tran J et al (2003) Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 10:390\u2013398","journal-title":"Menopause"},{"key":"9548_CR68","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdl304","volume":"17","author":"C Mathias","year":"2006","unstructured":"Mathias C, Cardeal MC, Ponde de SE et al (2006) An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann Oncol 17:1792\u20131796","journal-title":"Ann Oncol"},{"key":"9548_CR69","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1345\/aph.1A195","volume":"36","author":"RS Gregorian","year":"2002","unstructured":"Gregorian RS, Golden KA, Bahce A et al (2002) Antidepressant-induced sexual dysfunction. Ann Pharmacother 36:1577\u20131589","journal-title":"Ann Pharmacother"},{"key":"9548_CR70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1188\/05.ONF.329-342","volume":"32","author":"CE Jansen","year":"2005","unstructured":"Jansen CE, Miaskowski C, Dodd M et al (2005) Chemotherapy-induced cognitive impairment in women with breast cancer: a critique of the literature. Oncol Nurs Forum 32:329\u2013342","journal-title":"Oncol Nurs Forum"},{"key":"9548_CR71","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.bjc.6603029","volume":"94","author":"V Jenkins","year":"2006","unstructured":"Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828\u2013834","journal-title":"Br J Cancer"},{"key":"9548_CR72","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jnci\/90.3.210","volume":"90","author":"FS Dam van","year":"1998","unstructured":"van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210\u2013218","journal-title":"J Natl Cancer Inst"},{"key":"9548_CR73","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/13803390490510905","volume":"26","author":"SA Castellon","year":"2004","unstructured":"Castellon SA, Ganz PA, Bower JE et al (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955\u2013969","journal-title":"J Clin Exp Neuropsychol"},{"issue":"Suppl 3","key":"9548_CR74","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.3816\/CBC.2002.s.018","volume":"3","author":"TA Ahles","year":"2002","unstructured":"Ahles TA, Saykin AJ (2002) Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3(Suppl 3):S84\u2013S90","journal-title":"Clin Breast Cancer"},{"key":"9548_CR75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/pon.709","volume":"13","author":"V Jenkins","year":"2004","unstructured":"Jenkins V, Shilling V, Fallowfield L et al (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 13:61\u201366","journal-title":"Psycho-Oncology"},{"key":"9548_CR76","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuroimage.2003.08.037","volume":"21","author":"JL Eberling","year":"2004","unstructured":"Eberling JL, Wu C, Tong-Turnbeaugh R et al (2004) Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage 21:364\u2013371","journal-title":"NeuroImage"},{"key":"9548_CR77","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnci\/94.8.592","volume":"94","author":"T Ernst","year":"2002","unstructured":"Ernst T, Chang L, Cooray D et al (2002) The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 94:592\u2013597","journal-title":"J Natl Cancer Inst"},{"key":"9548_CR78","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jnci\/94.8.547","volume":"94","author":"PA Ganz","year":"2002","unstructured":"Ganz PA, Castellon SA, Silverman DH (2002) Estrogen, tamoxifen, and the brain. J Natl Cancer Inst 94:547\u2013549","journal-title":"J Natl Cancer Inst"},{"key":"9548_CR79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pon.821","volume":"14","author":"B Cimprich","year":"2005","unstructured":"Cimprich B, So H, Ronis DL et al (2005) Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology 14:70\u201378","journal-title":"Psycho-Oncology"},{"key":"9548_CR80","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jsbmb.2005.04.005","volume":"95","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J (2005) Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 95:143\u2013149","journal-title":"J Steroid Biochem Mol Biol"},{"key":"9548_CR81","first-page":"25","volume":"20","author":"D Cella","year":"2006","unstructured":"Cella D (2006) Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology (Williston Park) 20:25\u201328","journal-title":"Oncology (Williston Park)"},{"key":"9548_CR82","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.seminoncol.2003.08.020","volume":"30","author":"B Leyland-Jones","year":"2003","unstructured":"Leyland-Jones B, O\u2019Shaughnessy JA (2003) Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications. Semin Oncol 30:174\u2013184","journal-title":"Semin Oncol"},{"key":"9548_CR83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3816\/CBC.2005.n.002","volume":"5","author":"JA O\u2019Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy JA, Vukelja SJ, Holmes FA et al (2005) Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5:439\u2013446","journal-title":"Clin Breast Cancer"},{"key":"9548_CR84","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archneur.57.2.260","volume":"57","author":"Finelli","year":"2000","unstructured":"Finelli PF, Carley MD (2000) Cerebral venous thrombosis associated with epoetin alfa therapy. Arch Neurol 57:260\u2013262","journal-title":"Arch Neurol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-007-9548-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-007-9548-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T14:36:13Z","timestamp":1587911773000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-007-9548-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,18]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["9548"],"URL":"https:\/\/doi.org\/10.1007\/s10549-007-9548-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,18]]}}}